5 years ago

PolyProx Therapeutics Secures £1 Million in Seed Funding to Advance Cancer Therapies

  • PolyProx Therapeutics, a Cambridge, England-based biotechnology company, has raised an additional £1m in seed funding from LifeArc, joining existing investors Cambridge Innovation Capital, RT Capital, and Cambridge Enterprise

  • The company will use the funds to deliver in vivo proof of concept data for polyproxin® molecule leads against two oncology drug targets, which will form the basis for Series A financing in 2021

  • PolyProx Therapeutics is developing polyproxin® molecules that target and remove disease-causing proteins using the natural degradation machineries contained within the cell

  • The company's initial focus is on developing polyproxin® molecule candidates for use in the treatment of cancers, targeting aberrant proteins that have previously proven difficult to target using conventional drug classes.

      • ProblemHealthcare

      "Developing effective treatments for cancer remains a major challenge, particularly for targeting proteins that have been difficult to address with conventional drugs. "

      Solution

      "PolyProx Therapeutics is developing polyproxin® molecules, which target and remove disease-causing proteins using the cell's natural degradation mechanisms. They aim to create treatments for cancers by targeting specific proteins that have proven difficult to target with existing drugs."

      Covered on